Overview
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
The pipeline drugs are synthetic, highly specific compunds
targeting the A3AR with nM affinity and induce death (apoptosis) of
inflammatory and cancer cells via a molecular mechanism that includes deregulation
of the NF-kB and the Wnt signal transduction pathways. All drugs are
orally bioavailable with an excellent safety profile tested in close to 2000
patients.
Namodenoson (CF102), Can-Fite's drug candidate, is an oral drug currently in a pivotal Phase III for the treatment of advanced liver cancer (hepatocellular carcinoma), Phase IIa for pancreatic cancer and Phase IIb for MASH (metabolic-associated steatohepatitis; previously known as NASH).
Piclidenoson (CF101), Can-Fite's drug candidate, is an oral drug for the treatment of psoriasis. The FDA and EMA approved a pivotal Phase III clinical protocol and this clinical study will be initiated shortly.
CF602, an allosteric modulator at the A3AR, is earmarked for the treatment of sexual dysfunction and currently in a pre-clinical stage. CF602 showed efficacy in preclinical pharmacology studies demonstrating that topical and oral treatment significantly improved erectile function via an increase in smooth muscle/collagen ratio, VEGF and eNOS.
Cannabinoids induce their therapeutic effects via binding to Can-Fite's drug target, the A3AR. Based on this characteristic, Can-Fite can predict whether a given cannabinoid will be clinically efficacious. This know-how is patent pending and is currently in pre-clinical pharmacology studies..
Out-Licensing Deals: Piclidenoson for the treatment of psoriasis has been out-licensed to Cipher Pharmaceuticals in Canada; Gebro Pharma GmbH in Spain, Switzerland & Austria; Kyongbo Pharm in Korea; and CMS in China, Taiwan, Hong Kong and Macao. Piclidenoson has been out-licensed to Vetbiolix for the treatment of pet Osteoarthritis. Namodenoson for the treatment of liver cancer and MASH has been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea, CMS in China and the Swiss company Ewopharma, for Eastern Europe.
An advanced clinical stage
The Company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address inflammatory, liver and metabolic diseases.
Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine
receptor (A3AR) as a therapeutic target. The latter is highly expressed in
inflammatory, cancer and other pathological body cells, whereas low expression
is found in normal cells, suggesting that the receptor could be a specific and unique
target for pharmacological intervention.
Namodenoson (CF102), Can-Fite's drug candidate, is an oral drug currently in a pivotal Phase III for the treatment of advanced liver cancer (hepatocellular carcinoma), Phase IIa for pancreatic cancer and Phase IIb for MASH (metabolic-associated steatohepatitis; previously known as NASH).
Piclidenoson (CF101), Can-Fite's drug candidate, is an oral drug for the treatment of psoriasis. The FDA and EMA approved a pivotal Phase III clinical protocol and this clinical study will be initiated shortly.
CF602, an allosteric modulator at the A3AR, is earmarked for the treatment of sexual dysfunction and currently in a pre-clinical stage. CF602 showed efficacy in preclinical pharmacology studies demonstrating that topical and oral treatment significantly improved erectile function via an increase in smooth muscle/collagen ratio, VEGF and eNOS.
Cannabinoids induce their therapeutic effects via binding to Can-Fite's drug target, the A3AR. Based on this characteristic, Can-Fite can predict whether a given cannabinoid will be clinically efficacious. This know-how is patent pending and is currently in pre-clinical pharmacology studies..
Out-Licensing Deals: Piclidenoson for the treatment of psoriasis has been out-licensed to Cipher Pharmaceuticals in Canada; Gebro Pharma GmbH in Spain, Switzerland & Austria; Kyongbo Pharm in Korea; and CMS in China, Taiwan, Hong Kong and Macao. Piclidenoson has been out-licensed to Vetbiolix for the treatment of pet Osteoarthritis. Namodenoson for the treatment of liver cancer and MASH has been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea, CMS in China and the Swiss company Ewopharma, for Eastern Europe.